Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer

In brief

RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells. PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.

Key facts

Study ID

NCT00006340

Run by

Boston Medical Center

Starts

1994-12-01

Expected to finish

2000-07-01

Last updated by the study team

2013-07-26

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Methodist Cancer Center at Methodist Hospital — Indianapolis, Indiana, United States
• Cancer Research Center at Boston Medical Center — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Hopital Necker — Paris, France
• Medizinische Hochschule Hannover — Hanover, Germany
• Istituto Nazionale per lo Studio e la Cura dei Tumori — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.